Stifel analyst Nathan Jones upgraded Xylem (XYL) to Buy from Hold with a price target of $124, up from $115, after the company entered into a definitive agreement to acquire Evoqua (AQUA) in an all-stock transaction. The "low fundamental risk acquisition" provides "strong opportunity to drive higher growth together than separate," the analyst tells investors in a research note. The firm says Xylem shares are "on sale" following yesterday’s selloff and that the deal "is compelling just considering the cost synergies."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XYL:
- Xylem stock reaction to Evoqua deal ‘confounding,’ says Stifel
- Xylem’s buyout of Evoqua ‘pricey,’ with no accretion, says Raymond James
- Xylem falls -9.9%
- Xylem falls -8.7%
- Xylem Tanks on $7.5B Evoqua Acquisition
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue